CARVYKTI Shows Durable Treatment-Free Remissions at 2.5 Years in Earlier-Line Multiple Myeloma
Key Insights
Johnson & Johnson reported that 80% of standard-risk patients with relapsed or refractory multiple myeloma (search) remained progression-free and treatment-free at 2.5 years following a single CARVYKTI infusion as early as second-line therapy.
All 26 patients who achieved minimal residual disease-negative complete response at 12 months remained progression-free at 30 months, demonstrating the potential for long-term remission.
Translational analyses revealed that patients receiving CARVYKTI in earlier treatment lines showed improved immune fitness with increased baseline CD4+ naïve T cells (search), correlating with longer progression-free survival.
Johnson & Johnson announced updated results from the Phase 3 CARTITUDE-4 study demonstrating that CARVYKTI (ciltacabtagene autoleucel) can provide lasting treatment-free remissions when used as early as second-line therapy in patients with relapsed or refractory multiple myeloma (search). The data, presented at the 2025 American Society of Hematology Annual Meeting, showed that 80% of as-treated patients with standard-risk cytogenetics remained progression-free and treatment-free at 2.5 years following a single infusion.
Sustained Efficacy in Earlier Treatment Lines
In the CARTITUDE-4 analysis, 176 patients received CARVYKTI as early as second line, with 59 patients having standard-risk cytogenetics. At a median follow-up of 33.6 months, the 30-month progression-free survival rate among standard-risk patients appeared to plateau at 80.5% (95% CI, 67.2–88.8) following a single CARVYKTI infusion.
The results were particularly striking for patients who achieved deep responses. All 26 patients (100%) from the standard-risk group who achieved minimal residual disease (MRD)-negative complete response at 12 months following CARVYKTI infusion remained progression-free at 30 months.
"These data suggest that a single infusion of CARVYKTI for standard-risk patients may provide additional benefit to patients as early as second line of therapy," said Luciano J. Costa, M.D., Ph.D., Professor of Medicine at the University of Alabama and principal investigator of the CARTITUDE-4 study. "Treating patients with multiple myeloma (search) after first relapse offers the opportunity to achieve deeper and more durable responses, shifting the treatment paradigm closer to the possibility of long-term remission and, ultimately, cure."
Immune Fitness Correlates with Treatment Timing
Translational analyses from both CARTITUDE-1 and CARTITUDE-4 studies revealed important insights into the relationship between treatment timing and immune function. Patients receiving CARVYKTI after one or two prior lines of therapy demonstrated stronger immune fitness compared to those with three or more prior treatments, characterized by increased baseline CD4+ naïve T cells (search) in peripheral blood.
Bone marrow tumor analyses from CARTITUDE-4 patients also showed a more immune-activated profile in those treated after one prior line of therapy versus three. These biomarker findings identify potential immunologic factors associated with longer progression-free survival and support the improved outcomes seen with earlier CARVYKTI treatment.
Expanding Clinical Experience
The results add to a growing body of evidence supporting CARVYKTI's efficacy across diverse patient populations. More than 9,000 patients have been treated with CARVYKTI globally, providing comprehensive real-world experience that supports expanding use into earlier treatment settings.
"Our goal is to treat patients as early as possible, when they have the best chance for lasting remission," said Jordan Schecter, M.D., Vice President, Research & Development, Multiple Myeloma (search), Johnson & Johnson Innovative Medicine. "With more than 9,000 patients treated globally, CARVYKTI has demonstrated robust efficacy as soon as first relapse and is the first and only CAR-T to significantly extend overall survival versus standard therapies."
Study Design and Patient Population
CARTITUDE-4 is the first randomized Phase 3 study evaluating CARVYKTI's efficacy and safety, comparing the CAR-T therapy with standard of care treatments (PVd or DPd) in adult patients with relapsed and lenalidomide-refractory multiple myeloma (search) who received one to three prior lines of therapy. The study's primary endpoint is progression-free survival, with safety, overall survival, minimal residual disease negative rate, and overall response rate as secondary endpoints.
The CARTITUDE-1 study, a Phase 1b/2 open-label multicenter trial, evaluated CARVYKTI in heavily pretreated patients with relapsed and/or refractory multiple myeloma (search). In this population, 99% were refractory to their last line of treatment and 88% were triple-class refractory, meaning their cancer no longer responded to an immunomodulatory agent, proteasome inhibitor, and anti-CD38 antibody.
Current Regulatory Status
CARVYKTI received FDA approval in February 2022 for adults with relapsed or refractory multiple myeloma (search) after four or more prior lines of therapy. In April 2024, the approval was expanded to include patients who have received at least one prior line of therapy including a proteasome inhibitor and immunomodulatory agent, and who are refractory to lenalidomide, making it the first and only cell therapy approved for this earlier-line indication.
The European Medicines Agency similarly approved a Type II variation in April 2024 for treatment of adults with relapsed and refractory multiple myeloma (search) who have received at least one prior therapy, including an immunomodulatory agent and proteasome inhibitor, have demonstrated disease progression on the last therapy, and are refractory to lenalidomide.
Treatment Mechanism and Manufacturing
CARVYKTI is a BCMA (search)-directed, genetically modified autologous T-cell immunotherapy that reprograms a patient's own T-cells with a transgene encoding a chimeric antigen receptor (CAR). The CAR directs T-cells to eliminate cells expressing BCMA, which is primarily found on malignant multiple myeloma (search) B-lineage cells, as well as late-stage B cells and plasma cells.
The CARVYKTI CAR protein features two BCMA (search)-targeting single domains designed to confer high avidity against human BCMA. Upon binding to BCMA-expressing cells, the CAR promotes T-cell activation, expansion, and elimination of target cells. Johnson & Johnson entered into an exclusive worldwide license and collaboration agreement with Legend Biotech USA (search) in December 2017 to develop and commercialize the therapy.